Plain-English translation of NCT06919562 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
This trial is testing a second-generation bioresorbable scaffold (a special type of dissolvable stent called Meres100) for patients who need an artery-opening procedure. Unlike traditional metal stents that stay in your artery forever, this new stent is designed to dissolve over time, potentially allowing your artery to function more naturally. The trial combines this thinner new stent with advanced imaging tools and a specific placement technique to reduce the risk of problems.
The first generation of dissolvable stents had slightly higher failure rates than traditional metal stents, so researchers have made improvements โ thinner materials, better placement methods, and real-time imaging guidance โ that haven't yet been tested together in a careful study.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
You would undergo a percutaneous coronary intervention (PCI) โ a catheter-based procedure to open your blocked artery โ during which doctors would place the new dissolvable stent. Throughout the procedure, they would use advanced imaging (OCT or IVUS) to guide exact stent placement and check that it is positioned correctly. After the procedure, you would need to take blood-thinning medications as prescribed and follow standard post-procedure care and follow-up visits.
AI-generated summary from trial data ยท Jun 19, 2026 ยท Not medical advice
Netherlands